Category: News

Rail Vikas Nigam Limited (RVNL) shares, after peaking at ₹647 on the NSE in July 2024, have entered a prolonged base-building phase, dropping 44% from their all-time high. Over the past six months, the railway PSU stock has turned into a “sell-on-rise” candidate, reflecting subdued sentiment. Yet, analysts suggest the tide might turn in Q3 2025 as order flow remains robust, and institutional interest picks up following RVNL’s upgrade to large-cap status by AMFI. But Despite stock pressure, the company’s order flow was steady through October–December 2024, positioning RVNL for positive Q3 results even amid a sluggish Indian economy. Its promotion to the large-cap category by AMFI signals potential mutual fund interest, which could drive demand for the stock. RVNL shares are range-bound, trading between ₹348 and ₹365. A breakout above ₹365 could push the stock to ₹378–₹388 in the near term, with a medium-term target of ₹425. Conversely, a fall below ₹348 might lead to a dip toward ₹320. Analytics advises current investors to hold their positions with a stop-loss at ₹348. While the stock has struggled recently, its solid fundamentals, stable order book, and institutional interest hint at potential recovery. With disciplined trading strategies and an eye on technical indicators, RVNL could offer attractive opportunities for both current and new investors.

Shares of DroneAcharya Aerial Innovations bounced back on January 13, climbing nearly 8% intraday after the company announced a new collaboration with Tata Communications. The SME stock, surged to ₹110.60 following news of the ₹5.5 lakh order for a static drone designed for Tata Communications’ experience center. DroneAcharya highlighted the importance of this order, describing it as a strategic step toward establishing a robust partnership with Tata Communications. The announcement provided much-needed relief for investors, although the stock remains over 45% below its 52-week high of ₹202, recorded in January 2024. Over the past year, the company’s shares have shed more than 42% of their value, with January so far logging an 8% decline, following a modest 2.6% gain in December 2024. DroneAcharya, based in Pune and founded in 2017, is a key player in India’s growing drone industry, offering services like drone surveys, mapping, surveillance, and underwater inspection. Financially, DroneAcharya’s performance has been mixed. For the six months ending September 2024 (H1 FY25), the company reported a 62.1% drop in profit after tax to ₹1.50 crore, down from ₹3.96 crore in H1 FY24. However, operational revenue rose by 28.8% to ₹26.90 crore, bolstered by its expanding service portfolio.

Wockhardt shares defied market trends on January 13, surging by up to 4% in early trading. The stock opened at ₹1,375.05, touched a high of ₹1,441.95, and later traded 2.90% higher at ₹1,427 on the BSE by mid-morning. This performance came in the wake of the company’s announcement of a clinical breakthrough for its novel antibiotic, Zaynich (Zidebactam/Cefepime, WCK 5222). The groundbreaking drug, set to debut in India by the end of FY25 and globally in FY26, is anticipated to have no competition for at least 15 years. With the global antibiotic market estimated at $25 billion, Zaynich positions Wockhardt as a key player in addressing the pressing issue of drug-resistant infections. Wockhardt’s six antibacterial discovery programs, granted QIDP status by the USFDA, underscore its leadership in combating superbugs. The company derives 79% of its revenues from international markets, including the USA and Europe, bolstering its global presence. The stock has delivered stellar returns, gaining nearly 210% over the past year. Despite a flat performance in January so far, the stock logged gains of 23% in October, 16% in November, and 1% in December, showcasing resilience amid broader market challenges.

Kalyan Jewellers shares continued their losing streak on January 13, marking a seventh consecutive session of declines. The stock dropped 7% to ₹584, a 20-week low, bringing its total losses to 26% over the past week. Market experts attribute the downturn to heavy profit booking after an extraordinary rally from March 2023 to December 2024, during which the stock soared an impressive 651%. Despite the correction, the long-term fundamentals for the jewellery sector remain robust. Kalyan Jewellers recently posted a strong Q3 FY25 business update, showcasing a 41% year-on-year revenue growth, fueled by festive and wedding season demand across gold and studded jewellery categories. The Middle East division also performed well, with 22% revenue growth contributing 11% to the company’s consolidated revenue. Same-store sales grew by a solid 24% during the quarter. Even with the recent correction, Kalyan Jewellers has delivered remarkable returns, gaining 400% over two years and 751% over three years. The stock has closed 15 out of the last 20 months in the green, with standout gains of 44% in August 2023 and 29% in June 2024.

Amid a gloomy trading day, Piramal Pharma shares stole the spotlight, rallying over 9% during intraday trade on January 13 before closing 4.87% higher at ₹232.45 on the BSE. This marked the stock’s most significant intraday jump since November, defying a 1% dip in the Sensex. The rally comes after three consecutive losing sessions, with the stock rebounding sharply from its monthly decline of 12%. Buoyed by optimism around its contract development and manufacturing (CDMO) business, brokerage firms have recently upgraded their outlook. Jefferies raised its target price to ₹310, citing strong momentum in contract manufacturing and expectations of margin expansion through operating leverage. JM Financial, which initiated coverage in December with a target price of ₹340, is equally bullish. It foresees the Indian CRDMO market doubling by 2028, positioning Piramal Pharma as a key player thanks to its global footprint and end-to-end capabilities. The firm projects a 17% CAGR for the CDMO segment over the next three years, fueled by new molecules and a recovery in the US biotech sector. Beyond CDMO, the company’s complex hospital generics and consumer health segments are expected to deliver steady growth, contributing to a 15% topline CAGR from FY24 to FY27. Margins are also predicted to expand by 360 basis points, reaching 18%, driven by on-patent manufacturing.

PCBL, a heavyweight in carbon black manufacturing, had a rough start to the week, plummeting over 11% to ₹346.60, its lowest in five months. The selloff was triggered by disappointing Q3FY25 results, which unveiled a 37% YoY slump in net profit to ₹93 crore. The culprit? Soaring costs that overshadowed a modest revenue growth of 21.3%. Operating expenses shot up by 23%, with finance costs alone ballooning by a staggering 254%. Employee benefit expenses also jumped significantly, weighing further on profitability. While EBITDA climbed to ₹317 crore YoY, it marked a sequential drop from ₹364 crore, and operating margins shrank to 16%, down from last year’s 17%. Despite these challenges, PCBL pushed forward with its specialty chemical expansion at its Mundra plant, hitting a total capacity of 790,000 MTPA. The company also secured ISCC PLUS certification, signaling its focus on sustainable practices, and acquired 116 acres in Andhra Pradesh for a new plant, aiming to scale capacity to 1 million MTPA within a few years. While PCBL’s growth ambitions are noteworthy, the stock’s downward spiral underscores the immediate pressure from rising costs and tepid margins. Investors will need more than long-term plans to regain confidence—it’s all about delivering on operational efficiency and profitability in the coming quarters.

Even as the broader market stumbled, IndusInd Bank marched to its own beat on Monday, climbing over 3% to hit ₹973.30 on the BSE. The buzz? Hopes of a big-ticket passive fund inflow, thanks to a likely doubling of its MSCI weight in the February review. Foreign Portfolio Investors have been trimming their stakes, dropping from 55.53% in September to 46.63% by December. While that might sound like bad news, it’s actually created an opportunity—the bank’s “foreign room” now stands comfortably above the 25% threshold MSCI uses for weighting adjustments. If MSCI doubles the bank’s weight to 44 basis points from the current 22, we could see inflows north of $250 million. That’s the kind of liquidity injection that grabs attention. Market watchers predict these inflows will start shaping trading action in late February, coinciding with MSCI’s rebalancing date. For now, IndusInd’s stock is dancing within a tight range—support at ₹925 and resistance at ₹992-1,000. A decisive breakout will likely determine its next big move.With its recent underperformance compared to other banking peers, IndusInd’s current rally might just be the start of something bigger. All eyes are on whether this MSCI boost can flip the script for the stock in the weeks to come.

Standard Glass Lining Technology burst onto the trading floor with a flourish, listing at ₹172 on the NSE—a healthy 22.8% above its ₹140 issue price. Over on the BSE, it went a notch higher, debuting at ₹176, marking a 25.71% premium. For a company born in 2012 and laser-focused on serving India’s pharmaceutical and chemical industries, this IPO success feels like a well-deserved nod to its niche expertise. The IPO, which raked in ₹410 crore, turned out to be a crowd-puller. With bids stacking up 185.48 times the shares on offer, it wasn’t just a subscription; it was a stampede. Retail investors pitched in 65.71 times over their quota, and big-pocketed non-institutional buyers went all in with 275.21 times oversubscription. Qualified Institutional Buyers, who lined up with bids 327.76 times the allocation, underlining serious market confidence. A significant chunk of proceeds is earmarked for machinery and tech upgrades, aiming to sharpen operational efficiency. Another slice of the pie is heading toward debt reduction, including a cleanup of its subsidiary S2 Engineering’s financial slate. There’s also a forward-thinking plan to fund acquisitions and expand its global footprint, a leap from its current export revenue of 0.5% to an ambitious 20% by 2026. The financials don’t just look rosy—they shine. Analysts are optimistic, predicting a 20-25% revenue CAGR in the medium term, fueled by geographical and product diversification. Compared to its peers, Standard Glass boasts a premium margin profile, making its IPO valuation look grounded.

GTPL Hathway had a rough day on Friday, as its stock nosedived nearly 10 percent, hitting a 52-week low of ₹132.65. The tumble followed disappointing Q3FY25 earnings that left investors jittery. By the end of the session, the stock was trading a staggering 38 percent below its 52-week high of ₹215.05 from February 2024. The numbers told a tough story.  EBITDA dipped 12.8 percent to ₹113.80 crore, and margins shrank to 12.7 percent from 15.2 percent last year. Sequentially, the story wasn’t much better: profits slid 20 percent, though revenue edged up 3.7 percent. But not all signals flashed red. Subscriber growth across GTPL’s key segments provided a glimmer of hope. In the Digital Cable TV business, active and paying subscribers both increased by 200,000 year-on-year, reaching 9.6 million and 8.9 million, respectively. The Broadband segment also showed steady progress, with subscribers rising by 37,000 to hit 1.04 million. While GTPL Hathway’s financial performance this quarter raised concerns, its expanding subscriber base and focus on infrastructure upgrades suggest a potential turnaround. Investors will be watching closely to see if this growth momentum can offset the profitability crunch in the quarters ahead.

Jesons Industries, the Mumbai-based chemicals and adhesives player, has taken another swing at going public, refiling its draft red herring prospectus with SEBI. The company’s IPO game plan features a ₹300 crore fresh issue and an offer for sale of 9.46 million sharesa. Employees haven’t been left out, with a reserved portion and discounted bidding under the employee reservation category. On top of that, Jesons may explore a ₹60 crore private placement, which, if successful, will trim the fresh issue size accordingly. The fresh funds have a roadmap: ₹165 crore is earmarked to tackle outstanding debt, ₹77.9 crore will fuel capital expenditure through its subsidiary Jesons Innovative Polymers, focusing on setting up new production lines for solvent-based adhesives and flexible packaging adhesives. The rest is set aside for general corporate purposes, reinforcing the company’s growth ambitions. The IPO follows the book-building process, dividing the offer across investor types: half for institutional buyers, 15% for non-institutional investors, and 35% for retail bidders. Jesons aims to debut on both the NSE and BSE. This IPO is more than a funding exercise—it’s a strategic step to amplify Jesons’ presence in the industrial chemicals space while fueling its next phase of growth.